Moderna says updated Covid-19 vaccine recall shows stronger antibody response against Omicron

Bivalent boosters target two viral strains in the same vaccine. The updated booster contains Moderna’s original vaccine and a candidate vaccine that targets the Omicron variant.

The vaccine was generally well tolerated, the company said, with side effects similar to booster doses of the current vaccine.

The 50-microgram bivalent booster, called mRNA-1273.214, generated a stronger antibody response against Omicron than the original Moderna vaccine. Subvariants of Omicron are currently responsible for virtually all new cases of Covid-19 in the United States.

Stéphane Bancel, CEO of Moderna, said in a press release “we anticipate longer lasting protection against variants of concern with mRNA-1273.214, making it our lead candidate for a recall in fall 2022.”
He said the company will submit its preliminary data and analysis to regulators so that the bivalent booster containing Omicron will be available in late summer. U.S. Food and Drug Administration vaccine advisers are due to meet on June 28 to discuss whether coronavirus vaccine compositions need to be changed for fall 2022.

In April, Moderna announced its first bivalent Covid-19 booster candidate – which combined elements of the current vaccine with updates based on the beta variant – induced higher antibody responses against all variants of concern, including including Omicron, compared to the company. original Covid-19 booster injection.


Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor.
Back to top button